List of works - Michael J. Curtis

A novel adult human ventricle slice preparation for cardiac drug discovery and safety pharmacology ⬇️

scientific article published on 02 November 2011

A straightforward guide to the series of 'Straightforward Guide' reviews

scientific article published on 01 August 2014

Absolute beat-to-beat variability and instability parameters of ECG intervals: biomarkers for predicting ischaemia-induced ventricular fibrillation.

scientific article published on April 2014

Actions of flecainide on susceptibility to phase-2 ventricular arrhythmias during infarct evolution in rat isolated perfused hearts.

scientific article published on March 2006

Activation of IK1 by zacopride: amelioration of left ventricular remodeling, but at what risk?

scientific article published on 01 October 2014

Advice on statistical analysis, and new journal guidance for experimental design and analysis.

scientific article published in February 2015

Arrhythmogenic liability screening in cardiovascular safety pharmacology: commonality between non-clinical safety pharmacology and clinical thorough QT (TQT) studies.

scientific article published on 19 June 2010

Attrition in the drug discovery process: lessons to be learned from the safety pharmacology paradigm

scientific article published on 01 May 2012

BJP is changing its requirements for scientific papers to increase transparency.

scientific article published on 12 May 2015

Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist.

scientific article published on January 2015

Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative.

scientific article published on 10 April 2017

Characterisation, utilisation and clinical relevance of isolated perfused heart models of ischaemia-induced ventricular fibrillation ⬇️

scientific article published on 01 July 1998

Charge is an important determinant of hemodynamic and adverse cardiovascular effects of cationic drugs

scientific article published on 11 September 2015

Complex adrenergic and inflammatory mechanisms contribute to phase 2 ventricular arrhythmias in anaesthetized rats.

scientific article published on 16 January 2009

Contractile function assessment by intraventricular balloon alters the ability of regional ischaemia to evoke ventricular fibrillation

scientific article published on 17 September 2015

Development and characterization of a mouse in vitro model of ischaemia-induced ventricular fibrillation.

scientific article published on 19 February 2009

Does QT Widening in the Langendorff-perfused Rat Heart Represent the Effect of Repolarization Delay or Conduction Slowing? ⬇️

scientific article published on 01 November 2003

Emerging druggable targets for cardiovascular disease

scientific article published on 9 March 2009

Eponyms, priority, and attribution ⬇️

scientific article published on 01 December 1992

Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers

scientific article published in April 2018

Experimental design and analysis and their reporting: new guidance for publication in BJP.

scientific article published on July 2015

Expression and function of Kv7.4 channels in rat cardiac mitochondria: possible targets for cardioprotection.

scientific article published on 29 December 2015

Feasibility of targeting ischaemia-related ventricular arrhythmias by mimicry of endogenous protection by endocannabinoids.

scientific article published on August 2013

Haemodynamic Assessment in Safety Pharmacology

scientific article

Independent contribution of catecholamines to arrhythmogenesis during evolving infarction in the isolated rat heart. ⬇️

scientific article

Involvement of 5‐HT1B/1D and 5‐HT2A receptors in 5‐HT‐induced contraction of endothelium‐denuded rabbit epicardial coronary arteries ⬇️

scientific article published on November 1, 1997

Left regional cardiac perfusion in vitro with platelet-activating factor, norepinephrine and K+ reveals that ischaemic arrhythmias are caused by independent effects of endogenous "mediators" facilitated by interactions, and moderated by paradoxical

scientific article published on 05 April 2004

Limited antifibrillatory effectiveness of clinically relevant concentrations of class I antiarrhythmics in isolated perfused rat hearts.

scientific article published in March 2002

Mechanism of doxorubicin cardiotoxicity evaluated by integrating multiple molecular effects into a biophysical model.

scientific article published on 21 November 2017

Methodological innovations expand the safety pharmacology horizon ⬇️

scientific article published on May 20, 2012

Nitric oxide fails to confer endogenous antiarrhythmic cardioprotection in the primate heart in vitro.

scientific article published on 12 February 2007

Nitric oxide supplementation or synthesis block—which is the better approach to treatment of heart disease? ⬇️

scientific article published on July 1, 1997

Nupafant, a PAF-antagonist prototype for suppression of ventricular fibrillation without liability for QT prolongation?

scientific article published on 21 August 2006

Perception of validity of clinical and preclinical methods for assessment of torsades de pointes liability

scientific article published on 10 June 2008

Planning experiments: Updated guidance on experimental design and analysis and their reporting III

scientific article published on 7 June 2022

Potential role of cardiac chloride channels and transporters as novel therapeutic targets

scientific article

Proarrhythmia liability assessment and the comprehensive in vitro Proarrhythmia Assay (CiPA): An industry survey on current practice

scientific article published on 18 February 2017

Recalibration of nonclinical safety pharmacology assessment to anticipate evolving regulatory expectations

scientific article published on 22 June 2016

Replication - why we need to publish our findings

scientific article published on 24 July 2015

Reprint of "Safety pharmacology in 2014: New focus on non-cardiac methods and models".

scientific article published on 25 October 2014

Revision of instructions to authors for pharmacology research and perspectives: enhancing the quality and transparency of published work

scientific article published in March 2015

Safety pharmacology in 2014: new focus on non-cardiac methods and models

scientific article published on 14 August 2014

Safety pharmacology investigations in toxicology studies: an industry survey.

scientific article

Safety pharmacology investigations on the nervous system: An industry survey

scientific article

Structured prediction for differentiating between normal rhythms, ventricular tachycardia, and ventricular fibrillation in the ECG.

scientific article published in August 2015

The Diplomate in Safety Pharmacology (DSP) certification scheme.

scientific article published on 8 May 2015

The RETHINK project: impact of toxicity testing in the minipig as an alternative approach in regulatory toxicity testing

scientific article published on 06 August 2010

The Safety Pharmacology Society salary survey

scientific article published on 07 August 2017

The continuing evolution of torsades de pointes liability testing methods: is there an end in sight?

scientific article published on 18 December 2009

The isolated blood-perfused rat heart: an inappropriate model for the study of ischaemia- and infarction-related ventricular fibrillation.

scientific article published on December 2002

The shifting landscape of safety pharmacology in 2015.

scientific article published on 6 June 2015

Trapped platelets activated in ischemia initiate ventricular fibrillation

scientific article published on 31 August 2013

Troubleshooting pharmacological methods — Meeting an unmet need ⬇️

scientific article published on January 30, 2013

Ventricular cycle length irregularity affects the correlation between ventricular rate and coronary flow in isolated, Langendorff perfused guinea pig hearts

scientific article

List of works by Michael J. Curtis

A novel adult human ventricle slice preparation for cardiac drug discovery and safety pharmacology ⬇️

A straightforward guide to the series of 'Straightforward Guide' reviews

Absolute beat-to-beat variability and instability parameters of ECG intervals: biomarkers for predicting ischaemia-induced ventricular fibrillation.

Actions of flecainide on susceptibility to phase-2 ventricular arrhythmias during infarct evolution in rat isolated perfused hearts.

Activation of IK1 by zacopride: amelioration of left ventricular remodeling, but at what risk?

Advice on statistical analysis, and new journal guidance for experimental design and analysis.

Arrhythmogenic liability screening in cardiovascular safety pharmacology: commonality between non-clinical safety pharmacology and clinical thorough QT (TQT) studies.

Attrition in the drug discovery process: lessons to be learned from the safety pharmacology paradigm

BJP is changing its requirements for scientific papers to increase transparency.

Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist.

Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative.

Characterisation, utilisation and clinical relevance of isolated perfused heart models of ischaemia-induced ventricular fibrillation ⬇️

Charge is an important determinant of hemodynamic and adverse cardiovascular effects of cationic drugs

Complex adrenergic and inflammatory mechanisms contribute to phase 2 ventricular arrhythmias in anaesthetized rats.

Contractile function assessment by intraventricular balloon alters the ability of regional ischaemia to evoke ventricular fibrillation

Development and characterization of a mouse in vitro model of ischaemia-induced ventricular fibrillation.

Does QT Widening in the Langendorff-perfused Rat Heart Represent the Effect of Repolarization Delay or Conduction Slowing? ⬇️

Emerging druggable targets for cardiovascular disease

Eponyms, priority, and attribution ⬇️

Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers

Experimental design and analysis and their reporting: new guidance for publication in BJP.

Expression and function of Kv7.4 channels in rat cardiac mitochondria: possible targets for cardioprotection.

Feasibility of targeting ischaemia-related ventricular arrhythmias by mimicry of endogenous protection by endocannabinoids.

Haemodynamic Assessment in Safety Pharmacology

Independent contribution of catecholamines to arrhythmogenesis during evolving infarction in the isolated rat heart. ⬇️

Involvement of 5‐HT1B/1D and 5‐HT2A receptors in 5‐HT‐induced contraction of endothelium‐denuded rabbit epicardial coronary arteries ⬇️

Left regional cardiac perfusion in vitro with platelet-activating factor, norepinephrine and K+ reveals that ischaemic arrhythmias are caused by independent effects of endogenous "mediators" facilitated by interactions, and moderated by paradoxical

Limited antifibrillatory effectiveness of clinically relevant concentrations of class I antiarrhythmics in isolated perfused rat hearts.

Mechanism of doxorubicin cardiotoxicity evaluated by integrating multiple molecular effects into a biophysical model.

Methodological innovations expand the safety pharmacology horizon ⬇️

Nitric oxide fails to confer endogenous antiarrhythmic cardioprotection in the primate heart in vitro.

Nitric oxide supplementation or synthesis block—which is the better approach to treatment of heart disease? ⬇️

Nupafant, a PAF-antagonist prototype for suppression of ventricular fibrillation without liability for QT prolongation?

Perception of validity of clinical and preclinical methods for assessment of torsades de pointes liability

Planning experiments: Updated guidance on experimental design and analysis and their reporting III

Potential role of cardiac chloride channels and transporters as novel therapeutic targets

Proarrhythmia liability assessment and the comprehensive in vitro Proarrhythmia Assay (CiPA): An industry survey on current practice

Recalibration of nonclinical safety pharmacology assessment to anticipate evolving regulatory expectations

Replication - why we need to publish our findings

Reprint of "Safety pharmacology in 2014: New focus on non-cardiac methods and models".

Revision of instructions to authors for pharmacology research and perspectives: enhancing the quality and transparency of published work

Safety pharmacology in 2014: new focus on non-cardiac methods and models

Safety pharmacology investigations in toxicology studies: an industry survey.

Safety pharmacology investigations on the nervous system: An industry survey

Structured prediction for differentiating between normal rhythms, ventricular tachycardia, and ventricular fibrillation in the ECG.

The Diplomate in Safety Pharmacology (DSP) certification scheme.

The RETHINK project: impact of toxicity testing in the minipig as an alternative approach in regulatory toxicity testing

The Safety Pharmacology Society salary survey

The continuing evolution of torsades de pointes liability testing methods: is there an end in sight?

The isolated blood-perfused rat heart: an inappropriate model for the study of ischaemia- and infarction-related ventricular fibrillation.

The shifting landscape of safety pharmacology in 2015.

Trapped platelets activated in ischemia initiate ventricular fibrillation

Troubleshooting pharmacological methods — Meeting an unmet need ⬇️

Ventricular cycle length irregularity affects the correlation between ventricular rate and coronary flow in isolated, Langendorff perfused guinea pig hearts